Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

REPORT: Pharma steps up M&A, but specialty companies dominate

This article was originally published in Scrip

Executive Summary

Biopharmaceutical mergers and acquisitions more than doubled from $75bn in 2013 to $220bn in 2014 and big pharma played a larger role with $90bn in transactions last year aimed at boosting dwindling sales growth, but specialty pharmaceutical companies outspent their larger counterparts with $130bn in M&A deals with the goal of building portfolios that can compete on a global scale.

Topics

Related Companies

UsernamePublicRestriction

Register

SC027476

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel